ATYR · aTYR PHARMA INC
$0.55
+0.00 (+0.65%)
At close · Aug 27
Market Cap
$54.05M
Shares
98.09M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$190K
-19.1%
FY2025
Net Income
-$74.12M
-15.8%
FY2025
Operating Margin
-40856.32%
-11956.8pp
FY2025
Diluted EPS
-$0.80
+7%
FY2025
Operating Cash Flow
-$61.99M
+10.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $190K | $235K | $353K | $10.39M | $0 | $10.46M | $422K | — | — | — | — | — | — | |
| $47.09M | $60.22M | $54.37M | $42.29M | $42.81M | $23.26M | $17.29M | $14.05M | $20.39M | $30.07M | $42.85M | $34.5M | $16.78M | $13.83M | |
| $16.96M | $17.6M | $13.78M | $12.98M | $13.98M | $10.75M | $9.08M | $9.35M | $12.44M | $17.08M | $15.09M | $13.11M | $6.78M | $5.71M | |
| — | $664K | $708K | $592K | $232K | $475K | $569K | $635K | $746K | $713K | $900K | $869K | $829K | $714K | |
| $64.05M | $77.82M | $68.15M | $55.27M | $56.79M | $34.02M | $26.37M | $23.4M | $32.82M | $47.15M | $57.94M | $47.62M | $23.55M | $19.54M | |
| -$63.86M | -$77.63M | -$67.91M | -$54.92M | -$46.4M | -$34.02M | -$15.91M | -$22.98M | -$32.82M | -$47.15M | -$57.94M | -$47.62M | -$23.55M | -$19.54M | |
| — | -40856.32% | -28899.57% | -15557.79% | -446.79% | — | -152.19% | -5445.02% | — | — | — | — | — | — | |
| — | -$76.96M | -$67.21M | -$54.33M | -$46.17M | -$33.54M | -$15.34M | -$22.34M | -$32.07M | -$46.43M | -$57.04M | -$46.75M | -$22.73M | -$18.83M | |
| $3.05M | $3.5M | $3.89M | $4.52M | $1.06M | $238K | -$319K | -$785K | -$1.7M | -$1.06M | $36K | -$357K | -$796K | -$472K | |
| — | -$74.12M | -$64.02M | -$50.4M | -$45.34M | -$33.77M | -$16.23M | -$23.76M | -$34.52M | -$48.21M | -$57.9M | -$47.97M | -$24.35M | -$20.01M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | -$49K | — | — | — | |
| -$60.81M | -$74.12M | -$64.02M | -$50.39M | -$45.34M | -$33.77M | -$16.22M | -$16.22M | -$34.52M | -$48.21M | -$57.86M | -$47.97M | -$24.35M | -$20.01M | |
| — | -39009.47% | -27243.83% | -14274.5% | -436.53% | — | -155.18% | -3844.55% | — | — | — | — | — | — | |
| -$5000 | -$5000 | $1000 | -$8000 | -$5000 | -$9000 | -$6000 | -$160K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$48.21M | -$57.86M | -$47.99M | -$24.77M | -$21.65M | |
| -$60.8M | -$74.09M | -$63.99M | -$50.03M | -$45.51M | -$33.99M | -$16.23M | -$23.58M | -$34.46M | -$48.25M | -$57.76M | -$48.14M | -$24.35M | -$20.01M | |
| USD/shares | -$0.63 | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | — | — | — | — | — | — | — |
| USD/shares | -$0.63 | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | — | — | — | — | — | — | — |
| shares | — | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.85M | 23.68M | 15.84M | 834.22K | 762.76K |
| shares | — | 92.99M | 74.26M | 53.61M | 28.42M | 19.08M | 9.16M | 3.36M | 2.14M | 1.85M | 23.68M | 15.84M | 834.22K | 762.76K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.12×
EV/EBIT
—
Peer median 12.10×
P/E (TTM)
—
Peer median 8.71×
Peer medians compare against the 280 similar-size Biotechnology companies (of 517 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $200,000 | $200,000 | $400,000 | $10,000,000 | — | — |
| Additional Collaboration Revenue | — | — | $400,000 | $400,000 | — | — |
| Collaboration Revenue | — | — | — | $10,000,000 | — | — |
| License and Collaboration Revenues | — | — | — | $10,386,000 | $10,455,000 | — |
| License Revenue | — | — | — | — | — | $422,000 |
Key facts
CIK
1339970
CUSIP
002120202
13F (30d)
79 filings
78 filers
Visit website
Investor relations